Trade

Shukra Pharmaceuticals share price

Balanced risk
  • 42%Low risk
  • 42%Moderate risk
  • 42%Balanced risk
  • 42%High risk
  • 42%Extreme risk
  • 56.39(4.99%)
    December 16, 2025 15:15:35 PM IST
    • NSE
    • BSE
  • Vol : 451.34 K (NSE + BSE)
    Last 20 day avg : 390.40 K

Shukra Pharmaceuticals is trading 4.99% upper at Rs 56.39 as compared to its last closing price. Shukra Pharmaceuticals has been trading in the price range of 56.39 & 56.38. Shukra Pharmaceuticals has given 293.85% in this year & 27.49% in the last 5 days. Shukra Pharmaceuticals has TTM P/E ratio 135.98 as compared to the sector P/E of 28.49.The company posted a net profit of 2.38 Crores in its last quarter.Listed peers of Shukra Pharmaceuticals include Divi's Laboratories (-0.09%), Cipla (-0.48%), Sun Pharmaceutical Industries (-0.80%).The Mutual Fund holding in Shukra Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Shukra Pharmaceuticals was at -% in . The FII holding has - from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 16, 2025, 11:59 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -1.26
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.07
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.02
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    37.43
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    203.67
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    1.92
    Indicates Fair Valuation
Price range
Day Range
Lowest
56.38
Highest
56.39
52 week range
Lowest
7.63
Highest
53.71
Shukra Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
Neutral
6,341.00-0.091,68,204.8778.2711.470.460.01
Cipla
Bearish
1,500.00-0.481,21,165.6923.333.940.850.81
Sun Pharmaceutical Industries
Neutral
1,782.80-0.804,28,470.1437.946.040.880.50
Dr Reddy's Laboratories
Bullish
1,279.00-0.111,06,994.9218.803.170.632.34
Torrent Pharmaceuticals
Neutral
3,751.05-0.791,26,577.5466.6416.920.8417.62
Shukra Pharmaceuticals Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-13Quarterly Results
2025-10-03Others
2025-08-13Quarterly Results
2025-06-04Final Dividend
2025-05-29Audited Results
About the company Shukra Pharmaceuticals
  • IndustryBiotechnology & Drugs
  • ISININE551C01044
  • BSE Code524632
  • NSE Code
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.
  • Management Info
No Data
Management info for Shukra Pharmaceuticals is currently unavailable
Please check back later.
Shukra Pharmaceuticals Share Price FAQs

Shukra Pharmaceuticals is trading at 56.39 as on Tue Dec 16 2025 09:45:35. This is 4.99% upper as compared to its previous closing price of 53.71.

The market capitalization of Shukra Pharmaceuticals is 2469.20 Cr as on Tue Dec 16 2025 09:45:35.

The 52 wk high for Shukra Pharmaceuticals is 53.71 whereas the 52 wk low is 7.63

Shukra Pharmaceuticals can be analyzed on the following key metrics -

  • TTM P/E: 135.98
  • Sector P/E: 28.49
  • Dividend Yield: 0.02%
  • D/E ratio: 0.06

Shukra Pharmaceuticals reported a net profit of 9.58 Cr in 2025.